Joseph Patti, PhD

Joseph M. Patti, Ph.D. is President, Chief Executive Officer, and director of Evecxia Therapeutics, Inc. He is also a member of the board of directors of Armata Pharmaceuticals. Previously, he was President and Chief Executive Officer and an executive director at ZelamBio, Inc., AgilVax, Inc., and Aviragen Therapeutics. Prior to joining Aviragen, he co-founded Inhibitex, Inc. in 1994 and served as its Chief Scientific Officer and Senior Vice President of Research and Development until Bristol Myers Squibb acquired it in 2012. Before co-founding Inhibitex, Dr. Patti was an Assistant Professor at Texas A&M’s Institute of Biosciences and Technology and served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti received a B.S. in Microbiology from the University of Pittsburgh, a M.S.P.H. from the University of Miami, School of Medicine, and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.